论文部分内容阅读
为了探讨ＩＬ－２／ＬＡＫ细胞对中晚期癌症病人细胞免疫的影响，用３Ｈ－ＴｄＲ掺入ＤＮＡ法测定了１７例中晚期癌症病人在ＩＬ－２／ＬＡＫ细胞治疗前后外周血加ＰＨＡ或不加ＰＨＡ淋巴细胞体外增殖试验，结果显示无论空白对照（１１／１６）还是ＰＨＡ诱导的Ｔ淋巴细胞增殖试验（１２／１６），ｃｐｍ值较治疗前均有明显的提高（Ｐ＜０．０５，Ｐ＜０．０１）；在Ｔ细胞亚群的测定中，ＩＬ－２／ＬＡＫ细胞治疗前后比较，ＣＤ３＋和Ｃ８＋细胞都未发现明显的差异，只有Ｃ４＋细胞较治疗前（１３／１７）有了显著提高（Ｐ＜０．０１）；ＮＫ细胞虽未达到正常水平，但也显示较治疗前有显著增高的倾向；结果表明，ＩＬ－２／ＬＡＫ细胞疗法既对肿瘤细胞有直接杀伤作用，也对细胞免疫起了明显的促进作用。
To investigate the effect of IL-2/LAK cells on cellular immunity in patients with advanced cancer, we used 3H-TdR incorporation method to determine 17 patients with advanced cancer in peripheral blood plus or without PHA before and after treatment with IL-2/LAK cells. PHA lymphocyte proliferation assay in vitro showed that both the blank control (11/16) and PHA-induced T lymphocyte proliferation test (12/16), the cpm value was significantly higher than before treatment (P<0.05, P <0.01); In the determination of T cell subsets, no significant difference was found between CD3+ and C8+ cells before and after treatment of IL-2/LAK cells, and only C4+ cells had significant difference (13/17) before treatment. Increased (P<0.01); NK cells did not reach normal levels, but also showed a tendency to increase significantly before treatment; the results showed that IL-2/LAK cell therapy has a direct killing effect on tumor cells, but also Cellular immunity plays a significant role in promoting.